Cargando…
PCSK9 Inhibition: From Current Advances to Evolving Future
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine protease synthesized primarily by the liver. It mainly promotes the degradation of low-density lipoprotein receptor (LDL-R) by binding LDL-R, reducing low-density lipoprotein cholesterol (LDL-C) clearance. In addition to reg...
Autores principales: | Liu, Chunping, Chen, Jing, Chen, Huiqi, Zhang, Tong, He, Dongyue, Luo, Qiyuan, Chi, Jiaxin, Hong, Zebin, Liao, Yizhong, Zhang, Shihui, Wu, Qizhe, Cen, Huan, Chen, Guangzhong, Li, Jinxin, Wang, Lei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562883/ https://www.ncbi.nlm.nih.gov/pubmed/36230934 http://dx.doi.org/10.3390/cells11192972 |
Ejemplares similares
Ejemplares similares
-
Insight into the Evolving Role of PCSK9
por: Maligłówka, Mateusz, et al.
Publicado: (2022) -
Designer Functional Nanomedicine for Myocardial Repair by Regulating the Inflammatory Microenvironment
por: Liu, Chunping, et al.
Publicado: (2022) -
Homogeneous Polyporus Polysaccharide Inhibit Bladder Cancer by Resetting Tumor-Associated Macrophages Toward M1 Through NF-κB/NLRP3 Signaling
por: Liu, Chunping, et al.
Publicado: (2022) -
A Therapeutic Peptide Vaccine Against PCSK9
por: Pan, Yajie, et al.
Publicado: (2017) -
PCSK9: A Potential Therapeutic Target for Sepsis
por: Yuan, Yuan, et al.
Publicado: (2020)